ISA Pharmaceuticals

About:

ISA Pharmaceuticals is a developer of synthetic therapeutic vaccines designed to provide treatment for cancer.

Top Investors: European Investment Bank

Description:

ISA Pharmaceuticals B.V. is a clinical-stage immunotherapy company developing rationally designed, fully synthetic immunotherapeutics against cancer and persistent virus infections. The Company has built a proprietary immunotherapy platform based on its Synthetic Long Peptide (SLP®) concept and its AMPLIVANT® technology. SLP® immunotherapies are designed to fully harness and direct the body’s own defense mechanisms towards fighting the disease, either alone or in combination with existing therapies.

Total Funding Amount:

54M EUR

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Leiden, Zuid-Holland, The Netherlands

Founded Date:

2004-01-01

Contact Email:

info(AT)isa-pharma.com

Founders:

Cornelius Melief

Number of Employees:

11-50

Last Funding Date:

2021-07-13

IPO Status:

Private

Industries: